Compass Therapeutics (CMPX) filed a registration statement for the potential sale of up to $400 million of securities from time to time.
The shelf covers common and preferred stock, debt securities, warrants, and units, the company said Tuesday in a regulatory filing.
Net proceeds will be used for general corporate purposes.